LAVIPHARM S.A. NA EO 1 (F:BXA0) — Market Cap & Net Worth
Market Cap & Net Worth: LAVIPHARM S.A. NA EO 1 (BXA0)
LAVIPHARM S.A. NA EO 1 (F:BXA0) has a market capitalization of $242.59 Million (€207.50 Million) as of May 2, 2026. Listed on the F stock exchange, this Germany-based company holds position #15810 globally and #1515 in its home market, demonstrating a 11.58% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying LAVIPHARM S.A. NA EO 1's stock price €1.39 by its total outstanding shares 169043561 (169.04 Million). Analyse how efficiently does LAVIPHARM S.A. NA EO 1 generate cash to see how efficiently the company converts income to cash.
LAVIPHARM S.A. NA EO 1 Market Cap History: 2022 to 2026
LAVIPHARM S.A. NA EO 1's market capitalization history from 2022 to 2026. Data shows growth from $118.58 Million to $274.31 Million (19.69% CAGR).
LAVIPHARM S.A. NA EO 1 Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how LAVIPHARM S.A. NA EO 1's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
2.66x
LAVIPHARM S.A. NA EO 1's market cap is 2.66 times its annual revenue
Latest Price to Earnings (P/E) Ratio
15.69x
LAVIPHARM S.A. NA EO 1's market cap is 15.69 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2022 | $118.58 Million | $39.06 Million | $834.00K | 3.04x | 142.18x |
| 2023 | $151.78 Million | $47.84 Million | $1.87 Million | 3.17x | 81.12x |
| 2024 | $140.91 Million | $52.95 Million | $8.98 Million | 2.66x | 15.69x |
Competitor Companies of BXA0 by Market Capitalization
Companies near LAVIPHARM S.A. NA EO 1 in the global market cap rankings as of May 2, 2026.
Key companies related to LAVIPHARM S.A. NA EO 1 by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #499 globally with a market cap of $52.60 Billion USD.
- Zoetis Inc (NYSE:ZTS): Ranked #525 globally with a market cap of $50.31 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #526 globally with a market cap of $50.29 Billion USD ( CN¥343.70 Billion CNY).
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #572 globally with a market cap of $45.88 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #499 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #525 | Zoetis Inc | NYSE:ZTS | $50.31 Billion | $114.16 |
| #526 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $50.29 Billion | CN¥53.88 |
| #572 | GALDERMA GROUP AG | NYSE:GALDY | $45.88 Billion | $42.09 |
LAVIPHARM S.A. NA EO 1 Historical Marketcap From 2022 to 2026
Between 2022 and today, LAVIPHARM S.A. NA EO 1's market cap moved from $118.58 Million to $ 274.31 Million, with a yearly change of 19.69%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €274.31 Million | +64.45% |
| 2025 | €166.80 Million | +18.37% |
| 2024 | €140.91 Million | -7.16% |
| 2023 | €151.78 Million | +28.00% |
| 2022 | €118.58 Million | -- |
End of Day Market Cap According to Different Sources
On May 2nd, 2026 the market cap of LAVIPHARM S.A. NA EO 1 was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $242.59 Million USD |
| MoneyControl | $242.59 Million USD |
| MarketWatch | $242.59 Million USD |
| marketcap.company | $242.59 Million USD |
| Reuters | $242.59 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About LAVIPHARM S.A. NA EO 1
Lavipharm S.A. engages in the research, development, manufacture, import, marketing, sale, and wholesale of pharmaceutical, cosmetics, and healthcare products to physicians and pharmacists in Greece and internationally. The company offers pharmaceutical products for cardiology, oncology-urology, central nervous system, chronic pain, and self- treatment. It also provides prescription medicines and… Read more